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Abstract
Background: A breast cancer prognostic tool should ideally be applicable to all types of invasive breast lesions.
A number of studies have shown histopathological grade to be an independent prognostic factor in breast cancer,
adding prognostic power to nodal stage and tumour size. The Nottingham Prognostic Index has been shown to
accurately predict patient outcome in stratified groups with a follow-up period of 15 years after primary diagnosis
of breast cancer. Clinically, breast tumours that lack the expression of Oestrogen Receptor, Progesterone Receptor
and Human Epidermal growth factor Receptor 2 (HER2) are identified as presenting a “triple-negative” phenotype
or as triple-negative breast cancers. These poor outcome tumours represent an easily recognisable prognostic
group of breast cancer with aggressive behaviour that currently lack the benefit of available systemic therapy.
There are conflicting results on the prevalence of lymph node metastasis at the time of diagnosis in triple-negative
breast cancer patients but it is currently accepted that triple-negative breast cancer does not metastasize to axillary
nodes and bones as frequently as the non-triple-negative carcinomas, favouring instead, a preferentially
haematogenous spread. Hypothetically, this particular tumour dissemination pattern would impair the reliability of
using Nottingham Prognostic Index as a tool for triple-negative breast cancer prognostication.
Methods: The present study tested the effectiveness of the Nottingham Prognostic Index in stratifying breast
cancer patients of different subtypes with special emphasis in a triple-negative breast cancer patient subset versus
non- triple-negative breast cancer.
Results: We demonstrated that besides the fact that TNBC disseminate to axillary lymph nodes as frequently as
luminal or HER2 tumours, we also showed that TNBC are larger in size compared with other subtypes and almost
all grade 3. Additionally, survival curves demonstrated that these prognostic factors are equally important to stratify
different survival outcomes in non-TNBC as in TNBC. We also showed that the NPI retains the ability to stratify and
predict survival of TNBC patients.
Conclusion: The importance of this study relies on the need of prognostication improvements on TNBC, showing,
at a clinical standpoint, that Nottingham Prognostic Index is as a truthful prognostic tool in TNBC.
Background
Breast cancer comprises a complex and heterogeneous
group of diseases at clinical, morphological and molecu-
lar levels [1-3]. It is clear that breast tumours of the
same histological type show remarkably different clinical
behaviour, which is probably a reflex of their distinct
pattern of molecular aberrations [1,4]. Microarray tech-
nology has changed the way we understand breast
cancer classification by looking towards a molecular-
based approach instead the traditional morphology and
histopathological-based system [5,6]. Pioneered by the
Stanford group [6-9] and lately explored by several
other groups, a new taxonomy for breast cancer based
on expression profile has claimed that the morphologi-
cal heterogeneity of breast cancer can be recapitulated
and systematically classified at the transcriptomic level
and into clinically meaningful groups [10-12]. Such stu-
dies have shown that the molecular profile of breast
cancer present a systematic variation which allowed its
differential identification into two distinct branches [11],
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subtypes, and three ER-negative branch, which com-
prises at least, two reproducible subtypes: the HER2-
overexpressing group and the basal-like group
[6,8,9,13-15]. An additional group of tumours displaying
molecular features of normal breast tissue, and therefore
named as “normal-like”, has been also included in this
ER-negative branch. However, it has been suggested that
this group represents an artefact with high contamina-
tion from normal breast tissue rather than a distinct
molecular subtype [14]. Among the molecular subtypes
of breast cancer identified through gene expression pro-
filing studies, none has generated as much interest or
controversy as the basal-like breast cancer group (BBC)
[1]. Recently, a review published by a large group of
renown breast pathologists and clinicians, advocated
that there is still no internationally accepted definition
for BBC and discussed how best to define these tumours
[1]. Nevertheless, it is commonly accepted that the term
“basal-like” reflects the similarity of the protein expres-
sion profile of these tumours with the one of basal
epithelial cells of the normal mammary gland [16-19],
including high-molecular-weight cytokeratins (CK) 5/6,
14 and CK17, vimentin, P-cadherin, caveolins-1 and 2,
aB-crystalin and fascin [8,20-29]. BBC, the only group
consistently defined by gene expression arrays [30],
account for up to 15% of all breast cancers [1,11]. These
tumours frequently lack or show low levels of ER and
PR, lack HER2 overexpression and amplification
[21,31,32] and in approximately 85% of the cases display
p53 expression by immunohistochemistry or TP53
mutations [8,33]. Additionally, BBCs show exceedingly
high levels of proliferation-related genes [6,8,9,13] and
express EGFR in a significant number of cases [21,34].
Defined by microarray-based expression profiling or by
panels of immunohistochemical markers as surrogates,
BBCs are known by their clinically aggressive behaviour
[8,10,21,32].
Specimens that display BBC features (hormone recep-
tors and HER-2 lack of expression), are called, in rou-
tine practice, as “triple-negative” breast cancer (TNBC).
Controversial and provocative data has been recently
published questioning whether TNBC and BBC are
synonymous. Because a majority of BBCs are also
TNBCs and approximately 80% of TNBCs are also BBCs
[21,35], it has been claimed that the TNBC and BBC are
effectively synonymous [36,37]. However, clinical, micro-
array and immunohistochemical data have shown that
equating TNBC with BBC is misleading [15,33].
TNBC patients lack the benefit of routinely available
target therapy, which explains the undeniable growing
attention of both pathologists and oncologists as an
easily recognisable group of breast cancer with aggres-
sive behaviour and poor therapeutic options [2,38]. The
prognosis of women with TNBC is significantly poor,
compared to women with other subtypes of breast can-
cer. The higher recurrence and mortality rates of TNBC
patients may be in part explained by different routes of
metastatic spread [39]. There are conflicting results on
the prevalence of lymph node metastasis at the time of
diagnosis in TNBC patients [11]. Some studies described
a higher prevalence of lymph node metastasis in TNBC
[40], while others have found no statistical differences
[3] or even an inverse association between TNBC and
lymph node metastasis [41]. The currently accepted the-
ory is that TNBCs seems to disseminate to axillary
nodes and bones less frequently than the non-triple-
negative cancers, presenting a preferential haematogen-
ous route [32,42-44] with a proclivity to develop meta-
static deposits in the brain and lungs [11].
The Nottingham Prognostic Index (NPI) combines
nodal status, tumour size and histological grade [45],
reflecting metastatic behaviour, growth rate and genetic
instability of breast cancers [46,47]. Most importantly, as
a continuous variable, NPI offers a responsive and sensi-
tive means of modelling a continuum of clinical aggres-
siveness [46], indexing the outcome likelihood of invasive
breast cancer patients [48]. NPI can define 3 subsets of
patients with different probabilities of dying from breast
cancer; good (≤3.4), moderate (3.41 - 5.4), and poor (>
5.4) prognosis groups [48]. Three factors, found to be
independently associated with survival on multivariate
analysis, were combined to give the NPI algorithm. One
of these factors is the lymph node stage, which has tradi-
tionally been regarded as the most powerful prognostic
factor in breast cancer. The greater the number of nodes
involved, the worse the prognosis [45].
As above mentioned, TNBCs are believed to infre-
quently disseminate to axillary lymph nodes in favour of
distant and visceral metastatic spread [32,39,42], an
assumption that theoretically jeopardize the reliability of
using NPI as a tool for TNBCs prognostication, since
lymph nodal status is a major component for NPI
calculation.
Herein, we investigated a large series of breast tumours
and also a second cohort only composed by TNBC phe-
notype. These cohorts were used to test the clinical utility
of NPI in predicting breast cancer patient outcome.
Comparative analyses were performed within the TNBC
subgroup of patients in order to evaluate the contribution
of each Nottingham Prognostic components to the risk of
worse survival and prognosis in TNBCs.
Methods
Patient Selection
A series of 467 primary invasive breast carcinomas diag-
nosed between 1978 and 1992 were retrieved from the
Pathology Department, Hospital Xeral-Cíes, Vigo, Spain.
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submitted to therapeutic surgery and/or surgery plus
chemotherapy in the case of lymph node-positive
patients. The formalin-fixed paraffin-embedded histolo-
gical sections were reviewed and the diagnoses con-
firmed by two trained pathologists (FS and FM). The
tumours were characterized for clinical and pathological
parameters - namely age, tumour size, lymph-node sta-
tus, and histological grade (Table 1). Whenever was pos-
sible, NPI was calculated for each of the patients by
using the following equation: NPI = 0.2 × tumour size
(cm) + grade (1-3) + lymph node status (1-3) [47].
Patient follow-up information was available for 455
cases, ranging from a 1 to 120 months after the diagno-
sis. Overall and disease-free survival time was defined as
the time from the date of surgery to the date of death
or to the date of breast cancer derived relapse/metasta-
sis, respectively.
An additional cohort of 168 TNBC patients was
included in this study and analysed separately. This
cohort resulted from the combination of the 89 triple
negative tumours from the former series, plus 25 cases
from the Divino Espirito Santo Hospital (Ponta Del-
gada-Portugal), 29 cases from the Federal University of
Santa Catarina (Florianopolis-Brazil) and 25 cases from
the São João Hospital (Porto-Portugal). All these TNBC
specimens were evaluated and classified accordingly
with the same criteria and by the same panel of patholo-
gists. Patients followed the same therapeutic regimen
design as the general series.
This study was conducted under the national regula-
tive law for the handling of biological specimens from
tumour banks, being the samples exclusively available
for research purposes in retrospective studies.
Tissue microarray construction and
immunohistochemistry
Representative tumour areas were selected on haema-
toxylin-eosin-stained sections. At least two tissue cores
(0.6 mm in diameter) were obtained from each selected
specimen and deposited into a recipient paraffin block,
using a tissue microarray (TMA) workstation (Manual
Tissue Arrayer, Beecher Instruments, Inc.). The TMA
blocks were designed and built as previously described
[20] and non-neoplastic tissue cores were included as
controls.
In order to classify all breast cancer tumours according
with the molecular subtype, immunohistochemistry was
performed and the expression of breast cancer biomar-
kers [49], namely the hormonal receptors ER and PR, the
tyrosine kinase receptors HER2 and EGFR, the basal
cytokeratins CK5 and CK14, and also P-cadherin and
vimentin were evaluated. Immunohistochemical expres-
sion was detected using HRP polymer (Cytomation
Envision System HRP, DAKO, Carpinteria, CA), accord-
ing with the manufacturer’s instructions. Both methods
used diaminobenzidine as chromogen.
Immunohistochemical evaluation
The expression of ER, PR, HER2, EGFR, CK5, CK14, P-
cadherin and vimentin was evaluated according with the
grading systems previously described [49]. These immu-
nohistochemical results were used to classify the
Table 1 Patients characteristics and tumour parameters
Variable (N = 467) Data
Age at Diagnosis, years
Mean and standard deviation 59 ± 13
Range 64 (Min 28; Max 92)
Tumour Size (cm)
Mean and standard deviation 3.110 cm ± 2.00 cm
Range 15.6 (Min 0.4; max 16)
T1: < 2 cm 101 (24.7%)
T2: 2-5 cm 245 (59.9%)
T3: > 5 cm 63 (15.4%)
Not assessed 58
Lymph Node Invasion
Present 207 (56.6%)
Absent 159 (43.4%)
Not assessed 101
Histological Grade
Grade I 81 (18.3%)
Grade II 135 (30.5%)
Grade III 227 (51.2%)
Not assessed 24
Oestrogen receptor
Positive 309 (66.5%)
Negative 156 (33.5%)
Not assessed 2
Progesterone Receptor
Positive 228 (48.9%)
Negative 238 (51.1%)
Not assessed 1
HER2
Positive 68 (14.7%)
Negative 395 (85.3%)
Not assessed 4
Nottingham Prognostic Index
NPI < 3.4 99 (24.4%)
3.4 ≤ NPI ≤ 5.4 188 (46.4%)
NPI > 5.4 118 (29.2%)
Not assessed 62
Molecular Subtype
Luminal 343 (73.6%)
HER2 Over-expressing 33 (7.1%)
Triple Negative 90 (19.3%)
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namely Luminal, HER2-OE and Triple-negative (TNBC).
Statistical analysis
Statistical analysis was performed using SPSS statistics
17.0 software (SPSS Inc., Chicago, IL, USA). Continuous
variables were presented as the mean standard deviation,
and categorical variables were presented as number
(percentage). Mean differences for continuous variables
such as tumour size was performed using unpaired T-
test with a 95% confidence interval. Association between
different expression subtypes and the clinicopathological
features were assessed by Pearson correlation and chi-
squared tests.
Survival curves were estimated by the Kaplan-Meier
method using the long-rank test to assess significant dif-
ferences in survival. Cox regression models were fitted
to estimate hazard ratios [(HR, 95% confidence interval
(CI))] for the classical prognostic factors that constitute
the Nottingham Prognostic Index, namely, tumour size,
tumour grade and lymph-node status (LNS). Similarly,
Cox regression was used to calculate HR for the NPI
scoring in different expression subtypes. For all analysis,
a significant level of 5% was considered.
Results
NPI as a predictor of survival in breast cancer subtypes
Using the follow-up survival data from 455 breast can-
cer patients, we stratified the breast-cancer-specific out-
come, according with the NPI status. The NPI ranged
from 2-8.4 (mean 4.8). In the whole series, and in line
with what has been shown, NPI was able to stratify
breast cancer patients into good, moderate and worse
prognosis in terms of overall and disease-free survival
(Figure 1A and 1B, respectively). The outcome stratifica-
tion ability of NPI was also tested in specific breast can-
cer expression profiles. The same strength of statistical
significance was also observed in the subset of luminal
tumours (Figure 1C and 1D). An interesting finding was
the one observed in the HER2-OE subgroup, where
none of the cases was scored as NPI < 3.4, reinforcing
the poor prognosis of this breast cancer subtype. Here,
although the Kaplan-Meier curves showed a clear differ-
ence between the survival of NPI > 5.4 and 3.4 < NPI <
5.4 patients, especially concerning overall-survival, the
statistical value was not significant (Figure 1E and 1F).
In the cohort of TNBC, unequivocal patient outcome
stratification was draw by the NPI status. Notably, only
one case was scored with NPI < 3.4, confirming the
aggressive behaviour pattern of these tumours. In fact,
in both overall and disease-free survival Kaplan-Meier
curves (Figure 1G and 1H), TNBC patients with NPI >
5.4 are clearly separated from the good/moderate out-
come curve, reinforcing not only the worse survival of
the high-scored-NPI TNBC patients, but also suggesting
the value of NPI as a predictor of survival in TNBC
patients.
Tumour size, histological grade and LNS in Luminal,
HER2-OE and TN breast cancer
Each clinical-pathological feature that constitutes the
NPI equation was explored in the context of luminal,
HER2-OE and TNBC groups. The mean tumour size
was calculated for the three breast cancer subgroups. As
shown in Table 2 the mean tumour size of TNBC was
visibly higher compared to the average size of HER2-OE
and luminal tumours, which displayed the lowest mean
size. Using unpaired comparison analysis (T-test, 95%
CI), to evaluate the signific a n c eo ft h ed i f f e r e n c ef o u n d
in tumour size between TNBC and each of the other
subtypes, we showed that tumour size of TNBC was sta-
tistically different from the luminal subtype (p < 0.001)
and from the HER2-OE subtype (p = 0.05). Concerning
histological grade, Chi-square test showed that there
was a significant association between grade and the dif-
ferent molecular subtypes (p < 0.0001). The Table 2
shows that 78% and 71% of the HER2-OE and TNBC
patients, respectively, were high-grade tumours, while
the frequency distribution of tumour grade among lumi-
nal subtype tumours was rather homogeneous. Interest-
ingly, a non-statistically significant association between
LNS and the different expression subtypes was observed,
showing that the occurrence of lymph-node metastiza-
tion is a similarly frequent event across all the molecular
subtypes, but most importantly, that the extension of
these lymph-node involvement is as relevant in TNBC
tumours (26.4%) as it is for luminal (29.4%) or HER2-
OE breast cancers (33.3%) (Table 2).
High-scored-NPI lesions and its relation with tumour size,
grade and LNS in a subset of TNBC
Using only the cohort of 164 TNBC patients, we evalu-
ated the association of each of the Nottingham Prognos-
tic components to the NPI augmentation. A boxplot
graphic (Additional file 1) was draw to show the signifi-
cant association of tumour size, histological grade and
lymph node status to high scores of NPI in TNBC.
Using Chi-square test we observed a strong association
between larger tumours (p < 0.0001), displaying high
histological grade (p < 0.0001) and with extensive lymph
node invasion (p < 0.0001), with the worst outcome
group, represented by NPI > 5.4 (Additional file 1).
Besides the evidence that nearly 72% of TNBC are grade
III tumours, therefore clearly contributing for a high
NPI, it is however important to stress that the contribu-
tion of LNS also clearly associates with high NPI. More-
over, similarly with what was shown for tumour larger
than 5 cm, all the TNBC with more than 3 metastatic
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Page 4 of 10Figure 1 Long term overall and disease-free survival in breast cancer subtypes according with Nottingham Prognostic Index.K a p l a n -
Meier plots for a general series comprising all subtypes of invasive breast tumours (A and B). As expected, NPI clearly separate different groups
with distinct outcomes, showing that patients with NPI > 5.4 presented a much worse prognosis compared with patients with moderate and
good prognosis; (C and D) Kaplan-Meier plots for luminal subtype breast carcinomas. NPI is similarly able to stratify breast cancer patient into
different survival outcomes; (E and F) Kaplan-Meier plots for HER2 subtype breast carcinomas. None of the patients encompassing this subgroup
presented a NPI < 3.4. Although lacking statistical association, NPI is still able to discriminate between moderate and poor prognosis patients; (G
and H) Kaplan-Meier survival plots for TNBC subtype. Most of the patients within this subtype fell into the group with NPI > 5.4. Even though,
NPI had the statistically significant power to stratify patients with distinct outcomes.
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showing that LNS is a determinant factor to predict
worse prognosis in TNBC patients.
Tumour size is theoretically associated with the
increased likelihood of lymph node invasion in breast
cancer. In fact, we demonstrated that in non-TNBC
there was a strong association (p < 0.0001) between
tumour size and LNS, where 47% of patients with
tumours larger than 5 cm presented extensive metastiza-
tion (Table 3). In TNBC patients, 44% of patients with
larger tumours also showed a significant trend (p <
0 . 0 0 1 )t od i s p l a ym o r ee x t e n s i v el y m p hn o d ei n v a s i o n
(Table 3). An additional analysis was also performed
considering the presence or absence of lymph nodes
involved, and herein, we observed that 61% of TNBCs
with sizes < 2 cm lacked lymph node involvement,
whereas approximately 78% of TNBCs with sizes > 5 cm
displayed axillary lymph node invasion. These results
showed that larger tumours frequently metastasize to
lymph nodes, either being non-triple negative or TNBC
lesions.
Significance of NPI components to breast cancer survival
and mortality risk in TNBC patients
To evaluate the relevance of each NPI component to the
survival of TNBC patients we used the follow-up data
available for the TNBC cohort and survival curves were
estimated by the Kaplan-Meier method. Survival curves
demonstrated that TNBC patients with larger breast
tumours showed a significant difference towards worse
survival time (p < 0.0001; Figure 2A). Similarly, TNBC
patient survival is seriously affected by the lymph node
status (p < 0.0001; Figure 2B).
As previously demonstrated by univariate hazard ana-
lysis [50], we also showed that tumour size, histological
grade and lymph node status were significant predictors
of overall survival in breast cancer series. The same Cox
proportional analysis was used to estimate the risk asso-
ciated to the survival difference found by Kaplan-Meier
curves in TNBC cohort. We observed that tumour size
was a significant predictor of survival in this subset of
tumours, showing that patients with larger tumours
carry about 3.2-fold-increased risk of breast cancer-
Table 2 Nottingham Prognostic Index components on triple-negative and non-triple-negative breast cancer subtypes
Nottingham Prognostic Index Components
Molecular Subtype Tumour Size
Mean ± St. Error
Tumour Grade Lymph Node Status
I II III None 1 < LNS < 3 LNS > 3
Luminal 2.92 cm ± 0.105 24.1% 38% 38% 43.9% 26.7% 29.4%
(N = 302) (N = 324) (N = 262)
HER-OE 3.08 cm ± 0.203 4.9% 16.5% 78.6% 42.4% 24.2% 33.3%
(N = 93) (N = 103) (N = 99)
Triple Negative (TNBC) 3.70 cm ± 0.211 4.9% 23.9% 71.2% 48.6% 25% 26.4%
(N = 155) (N = 163) (N = 148)
Luminal P-value*
Statistics TNBC vs
p < 0.001
P-value**
< 0.0001
P-value**
Not significant
HER2-OE P = 0.05
*ANOVA was used to compare the means of the three groups
** P-values were calculated with the use of the c
2 test
Table 3 Association of tumour size and lymph node status in triple-negative and non-triple-negative breast cancer
Non-Triple Negative Breast Cancer Triple Negative Breast Cancer
LNS None 1 < LNS < 3 LNS > 3 None 1 < LNS < 3 LNS > 3
TS
Tumour Size < 2 cm 66.7% 22.7% 10.7% 60.8% 32.1% 7.1%
Tumour Size 2-5 cm 39.4% 26.1% 34.5% 56.7% 19.8% 23.5%
Tumour Size > 5 cm 19.4% 33.3% 47.2% 22.2% 33.3% 44.5%
Statistics (N = 276) P-value*
< 0.0001
(N = 145) P-value*
< 0.001
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pared to breast cancer patients with tumours smaller
than 5 cm (Figure 2C). Notably, when risk analysis were
applied to lymph node status, we observed that TNBC
patients with more extensive lymph node invasion, hold
approximately 4.5-fold-increased risk of breast-cancer-
related death (HR = 4.50, 95% CI: 2.16 to 9.34), com-
pared to patients lacking axillary invasion (Figure 2C).
Discussion
The prognosis of women with TNBC is significantly
poor, compared to women with other subtypes of breast
cancer. The underlying difference in recurrence and
patient mortality rates may be explained in part by dif-
ferent routes of metastatic spread [51]. The current the-
ory point out to the suggestion that TNBCs metastasize
to axillary nodes and bones less frequently than the
non-triple-negative subset of breast tumours, favouring
a haematogenous spread [32,42-44].
In terms of survival, it has been described that the
survival curve shape for TNBC or BBC differs from that
of patients with other types of breast cancer: there is a
sharp decrease in survival during the first 3 to 5 years
after diagnosis, but distant relapse after this time is
much less common [31,40,41,52]. In a study published
by Dent and colleagues, the median time to death was
3.5 years for TNBC compared to 5.7 years for patients
with other cancers [39]. In fact, as we can infer by the
survival functions, TNBC experienced a severe decrease
in their outcome before 48 months, a curve shape that
overlaps with the one draw by the NPI in those patients.
These findings reinforce the reliability of NPI as a tool
to be reproducibly used in TNBC tumours.
In our cohort of TNBC we have found that tumour
size is considerably higher compared with other sub-
types of breast cancer. This difference in tumours size
was strongly significant in relation to luminal, but not
so marked when compared with HER2 tumours. Addi-
tionally, we found that, histologically, most TNBCs were
high grade tumours. These results concerning tumour
size and grade are largely in accordance with previous
studies where these prognostic factors were studied
within breast cancer subtypes, with special emphasis on
TNBC versus non-TNBC patients [40,50,53,54]. One of
these studies used a notably large series of TNBC (6.370
patients) and non-TNBC (44.704 patients), and similar
Figure 2 Significance of the NPI components to breast cancer mortality risk and survival in TNBC patients. Kaplan-Meier survival curves
for tumour size (A) and for lymph node status (B). Both NPI components are highly statistically relevant to predict long term survival in TNBC
patients; (C) Hazard ratio (CI 95%) in the TNBC cohort was calculated for tumour size and lymph node status. Patients with triple-negative
tumours larger than 5 cm display a 3.2-fold risk of death by breast cancer; Concerning axillary lymph node status, TNBC patients with lymphatic
involvement higher than 3 nodes have a 4.5-fold risk of breast-cancer specific death.
Albergaria et al. BMC Cancer 2011, 11:299
http://www.biomedcentral.com/1471-2407/11/299
Page 7 of 10findings concerning histological grade and tumour size
were found [53]. Interestingly, we found no difference
regarding lymph node metastization between luminal,
HER2-overexpressing tumours and TNBC. Thus,
although it has been suggested that TNBC tend to disse-
minate in a lower frequency to lymph nodes, we found
that 51.4% of TNBC developed metastasis to lymph
nodes. This percentage shows that 1) the lymph node
involvement in TNBC is as frequent as in other sub-
types of breast cancer and, 2) the extension of this
involvement do not differ between breast tumour sub-
types. In the last 4 years, interesting studies have
reported data concerning positive lymph node status in
TNBC compared to non-TNBC, describing percentages
of positive lymph nodes in TNBC ranging from 42.5%
[55] to 54.4% [40], therefore, corroborating the results
presented herein. Based on that, and even considering
some putatively less prominent lymph node involvement
in TNBC, which accordingly to our results was not
observed, tumour size and grade variables are someway
playing a compensatory score augmentation to NPI algo-
rithm. Additionally, survival curves concerning tumour
size and lymph node status demonstrated that these
prognostic factors are equally important to stratify survi-
val outcomes in non-TNBC as in TNBC. Taken together,
and considering that the majority of TNBC lesions are
grade III, these largely studied prognostic factors are reli-
able to be used in the assessment of NPI in TNBC. Inter-
estingly, we also found a slight association between
tumour size and lymph node status in TNBC. This result
contributes to some controversy concerning the existence
or not of a relationship between size and lymph node sta-
tus, since some authors already argued a lack of associa-
tion between these two prognostic factors in TNBC [40].
In our TNBC series, we have a proportion of 74% of
BBC. The discrepancies about the association between
tumour size and lymph node status could be explained if
the TNBC cohort used by Dent et al.w e r ee n r i c h e di n
basal-like breast tumours compared with the cohort we
studied here. These hypothesis lay on a robust study
recently published by Ellis group, where although a trend
(non-significant) to display lymph node involvement with
increasing tumour size was seen (especially in tumours
larger than 4 cm), basal-like tumours do not seem to
obey the “size-node” rule [56].
Conclusions
While basal-like tumours is a designation only revealed
by gene profiling signatures [6], TNBC is a clinico-
pathological classification which identifies a group of
breast cancer with aggressive behaviour [2,38], and
where improvements on therapy development and prog-
nostication are compulsory. In the study presented
herein, we demonstrated that besides the fact that
TNBC disseminate to axillary lymph nodes as frequently
as luminal or HER2 tumours, we also showed that
TNBC are larger in size compared with other subtypes
and almost all grade III, therefore making truthful, at a
clinical standpoint, the applicability of NPI as a prog-
nostic tool in TNBC.
Additional material
Additional file 1: Association of tumour size (A), histological grade
(B) and lymph node status (C) to high scores of NPI in TNBC. The
boxplot graphic show an association between larger tumours, displaying
high histological grade and with extensive lymph node invasion, with
tumours clustered into the worst outcome group, represented by NPI >
5.4 (p < 0.0001) (A, B and C). The graphic highlights the contribution of
lymph node status to the augmentation of NPI, showing that LNS is a
determinant factor to predict worse prognosis in TNBC patients.
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